China NMPA Drug Inspection - Anhui Hongxin Pharmaceutical Development Co., Ltd. - Salt plantain

The Shaanxi Provincial Drug Administration published its ninth Drug Quality Bulletin of 2020 on September 29, 2020, following a series of province-wide sampling inspections. The report identifies five specific batches of drugs that failed to meet quality standards. The non-compliant manufacturers include Anhui Hongxin Pharmaceutical Development Co., Ltd., Anhui Bozhou Qiancao Guoyao Co., Ltd., Ningxian Kangshengyuan Pharmaceutical Co., Ltd., Qingyang Yixiang Pharmaceutical Co., Ltd., and Shanxi Taiyuan Pharmaceutical Co., Ltd. The primary violations cited involve failures in physical appearance (characteristics), content determination, and general inspection parameters. All products were evaluated against the 2015 Edition of the Chinese Pharmacopoeia (Parts I and II). In response to these findings, the Shaanxi Provincial Drug Administration has instructed municipal and county-level regulatory bodies to implement immediate control measures on the affected batches. Furthermore, the involved units are currently under investigation, with legal and administrative actions being pursued in accordance with national drug safety laws to ensure public medication safety and industry compliance.